<DOC>
	<DOCNO>NCT01558674</DOCNO>
	<brief_summary>Part I 3-period , active comparator-controlled , fix sequence study evaluate safety , tolerability , pharmacokinetics pharmacodynamics MK-7145 compare furosemide participant moderate-to-severe renal insufficiency ( RI ) without heart failure ( HF ) . Primary hypothesis Part I least one well-tolerated dose MK-7145 produce great 24hr urinary excretion sodium ( UNa ) 1st day MK-7145 dose 80 mg furosemide ( 1st day furosemide dose ) participant moderate-to-severe RI . If MK-7145 safe natriuretic dos RI Part I study , MK-7145 investigate participant heart failure ( HF ) RI ( Part II ) . Part II 4 period , fix sequence , active comparator control ( Period 1 ) , titration ( Periods 2 , 3 4 ) study evaluate safety , tolerability , pharmacokinetics pharmacodynamics titration regimen MK-7145 compare optimize stable maintenance regimen furosemide torsemide participant New York Heart Association ( NYHA ) Class II III heart failure moderate severe renal insufficiency . The primary hypothesis Part II least one dose MK-7145 , titrate accord fix dose titration regimen , associate reduction N-terminal pro-brain natriuretic peptide ( NT-proBNP ) compare furosemide torsemide ( 24 hour post morning dose last dosing day period ) participant NYHA class II/III HF moderate severe RI .</brief_summary>
	<brief_title>A Study MK-7145 Participants With Renal Insufficiency ( Part I ) Heart Failure With Renal Insufficiency ( Part II ) ( MK-7145-011 )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Torsemide</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<criteria>Parts I II If female , must nonchild bear potential , childbearing potential agrees use least 2 acceptable contraceptive measure Body Mass Index ( BMI ) &gt; =17.5 &lt; =38 kg/m^2 No present history clinically significant uncontrolled arrhythmia electrocardiogram ( ECG ) Nonsmoker light smoker consume average 20 cigarette ( equivalent tobacco product ) per day . Part I Only Estimated creatinine clearance ≤45 mL/min . Part II Only Class II III heart failure specify New York Heart Association ( NYHA ) functional classification heart failure NTproBNP &gt; =1000 pg/mL clinically optimized therapy stable dose ( least 2 week ) furosemide torsemide Estimated creatinine clearance ≤45 mL/min Parts I II Mentally legally institutionalize and/or incapacitate , significant emotional problem history clinically significant psychiatric disorder last 5 year . This include mood disorder require concomitant use lithium Diagnosed acute coronary syndrome acute cardiovascular ( CV ) event , hospitalize HF exacerbation within less 3 month study entry Unstable angina pectoris Diabetes require high dose peroxisome proliferatoractivated receptor ( PPAR ) antagonist ( e.g . &gt; 30 mg pioglitazone ) unstable insulin use Infectious disease require concomitant use aminoglycosides Low plasma potassium ( hypokalemia ) Recent ( within 6 month ) history stroke , uncontrolled seizure , uncontrolled major neurological disorder Urinary retention , hydronephrosis hydroureter Active nephrocalcinosis , nephrolithiasis , hypercalciuria Functional disability interfere rise semirecumbent position stand position History malignant neoplastic disease Unable refrain use medication , include prescription nonprescription drug highdose aspirin ( ≥325 mg/day ) , nonsteroidal antiinflammatory drug ( NSAIDs ) , human immunodeficiency virus ( HIV ) protease inhibitor ( ritonavir , indinavir , nelfinavir ) , macrolide antibiotic ( erythromycin , telithromycin , clarithromycin ) , chloramphenicol , azole antifungal ( fluconazole , ketoconazole , itraconazole , nefazodone , aprepitant , verapamil , diltiazem , etc . ) , anticonvulsant mood stabilizer ( e.g. , phenytoin , carbamazepine , oxcarbazepine ) , barbiturates ( phenobarbital ) , HIV nonnucleoside reverse transcriptase inhibitor ( efavirenz , nevirapine , etravirine ) , rifampicin , modafinil , St John 's wort , cyproterone ( antiandrogen , progestin ) , etc . begin approximately 2 week ( 5 halflives ) , prior administration initial dose study drug , throughout study ( include washout interval treatment period ) poststudy visit Consumes excessive amount alcohol , define great 5 glass alcoholic beverage ( 1 glass approximately equivalent : beer [ 284 mL/10 ounce ] , wine [ 125 mL/4 ounce ] , distilled spirit [ 25 mL/1 ounce ] ) per day Consumes excessive amount , define great 6 serving ( 1 serve approximately equivalent 120 mg caffeine ) coffee , tea , cola , caffeinated beverage per day Had major surgery , donate lose 1 unit blood ( approximately 500 mL ) participate another investigational study within 4 week Regular user illicit drug history drug ( include alcohol ) abuse within approximately 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>